Results patients TT3 group, TT4, FT3, FT4 were obviously decreased with significant difference (p < 0.01).
效果病人组的TT3、TT4、FT3、FT4均显着降落，与比较组有显著的差异（p<0.01）。
Results: The levels of TSH, FT3, FT4 and CT in treated groups were increasing comparing with normal saline group.
结果：喂服中药组的血清tsh、FT3、FT 4、CT浓度均明显上升，与生理盐水组相比有显著统计学意义。
Serum FT3 levels might be a parameter to assess the clinical outcomes of patients with treatment-resistant depression.
血清ft3水平有可能成为难治性抑郁症患者的疗效评价指标。
Objective To investigate the protein depletion in patients with liver and kidney disease, FT3, FT4 in clinical application.
目标探究蛋白质消耗的肝肾疾病患者的FT 3、FT4在临床中应用代价。
Serum FT3 levels in effective group were significantly higher than those in ineffective group before and after treatment (P<0.05).
有效组患者治疗前后血清FT3水平均明显高于无效组（P<0.05）。
FT3 was significantly decreased in nephrotic syndrome patients, which suggested that nephrotic syndrome be a kind of euthyroid sick syndrome.
在肾病综合征患者，主要表现为FT 3显著降低，提示肾病综合征是正常甲状腺病态综合征的一种。
The significant decreasing of the mean value of FT3 and FT4 on the whole in this cohort may be reflecting aging decreasing of thyroid function.
从该群体整体看FT4及FT3值增龄性下降，可反映增龄性甲状腺功能减退。
The levels of serum free Triiodothyronine (FT3) and free Thyroxine (FT4) with thyroid-stimulating hormone (TSH) were measured by CLIA and RIA methods respectively.
分别采用CLIA与RIA法检测血清游离三碘甲状腺原氨酸（FT3）、游离甲状腺素（FT4）、促甲状腺激素（TSH）。
Serum thyroid stimulating hormone (TSH), free triiodothyronine (FT3) and free tetraiodothyronine (FT4) levels were detected after operation or 2, 3 and 4 weeks after drug withdrawl.
两组患者分别于术后或停药后第2、3、4周测定血清促甲状腺素(TSH)、游离三碘甲状腺原氨酸(FT3)和游离甲状腺素(FT4)水平。
Serum thyroid stimulating hormone (TSH), free triiodothyronine (FT3) and free tetraiodothyronine (FT4) levels were detected after operation or 2, 3 and 4 weeks after drug withdrawl.
两组患者分别于术后或停药后第2、3、4周测定血清促甲状腺素(TSH)、游离三碘甲状腺原氨酸(FT3)和游离甲状腺素(FT4)水平。
应用推荐